Nycomed reports double-digit growth across emerging markets in second quarter 2011
(Thomson Reuters ONE) -
Nycomed /
Nycomed reports double-digit growth across emerging markets in second quarter
2011
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Strong performance in emerging markets helped offset challenging conditions
in mature European markets; emerging markets accounted for 46.3% of Q2
turnover
* Total net turnover steady at ?786.2 million (+2.4% in local currencies),
with emerging markets growing 23.5% in local currencies
* Adjusted Q2 EBITDA down 4.5% at ?188.6 million (+2.2% in local currencies);
H1 EBITDA ?501.0 million, up 16.4%, including one-time Forest Laboratories
payment (+16.5% in local currencies)
* Partnerships progressing: Transfer of marketing authorisation approvals in
Asia-Pacific for Bonviva® (Ibandronate) from Roche completed and Turkish
portfolio strengthened; commercialization agreement with Allmirall for
roflumilast in Spain; Collaboration signed with Orion on Easyhaler®
combination products
* NDA submitted in US for ciclesonide nasal aerosol HFA formulation by US
partner Sunovion; Instanyl® single-dose spray approved in Europe
* Agreement with Takeda to acquire Nycomed announced in May 2011, subject to
antitrust clearance
The financial results reported in this press release are related to Nycomed
S.C.A. SICAR and comprise all of the Nycomed Group's operations. The full
interim report is available atwww.nycomed.com/Investors/Reports
Nycomed today announced results for the second quarter of 2011, achieving double
digit growth across emerging markets. Good progress was made in Key Products,
particularly in the respiratory area. Following U.S. approval of Daliresp(TM)
for the treatment of COPD earlier this year, Nycomed's partner Forest
Laboratories introduced the product to the market and is preparing a full launch
in the third quarter. In May, Nycomed agreed to be acquired by Takeda, subject
to antitrust clearance, creating a truly global pharmaceutical business equipped
to meet the needs of patients, doctors and healthcare providers.
Net turnover in the second quarter was stable compared with the second quarter
2010, up 2.4% in local currencies to ?786.2 million.
Strong growth was achieved in Asia-Pacific, Africa and Middle East (+80.8% in
Q2, +68.8% in H1 in local currencies), Russia/CIS (+10.9% in Q2, +20.5% in H1 in
local currencies) and Latin America (+5.5% in Q2, +10.0% in H1 in local
currencies) continued to grow, offsetting the challenging conditions in the US
and Western Europe.
Commenting on the company's second quarter performance, Nycomed CEO Håkan
Björklund said: "We again saw the success of our increasing focus on emerging
markets in the second quarter, with strong performances in areas such as Asia,
Middle East and Latin America helping to offset anticipated declines in some of
the more mature markets of Western Europe and the US.
We look forward to closing the agreement with Takeda for the acquisition of
Nycomed announced in May and to creating a truly global pharmaceutical business
equipped to meet the needs of patients, doctors and healthcare providers.
Nycomed ends the first half of 2011 in excellent shape and looks forward to an
even brighter future."
Key figures
+-----------------------+-------+-------+-------+-------+-------+--------+
| |Q2 2011|Q2 2010|Change |H1 2011|H1 2010|Change |
| |(?m) |(?m) | |(?m) |(?m) | |
+-----------------------+-------+-------+-------+-------+-------+--------+
Net turnover 786.2 786.5 0.0% 1,710.0 1,562.9 9.4%
2.4%(1) 8.9%(1)
--------------------------------------------------------------------------
Gross profit 549.9 552.1 -0.4% 1,221.4 1,100.2 11.0%
Margin 69.9% 70.2% 71.4% 70.4%
--------------------------------------------------------------------------
Operating profit (EBIT) 45.8 16.1 184.5% 213.3 57.6 270.3%
--------------------------------------------------------------------------
EBITDA 175.8 188.5 -6.7% 469.8 401.0 17.2%
Margin 22.4% 24.0% 27.5% 25.7%
--------------------------------------------------------------------------
Adjusted EBITDA 188.6 197.4 4.5% 501.0 430.4 16.4%
2.2%(1) 16.5%(1)
Margin 24.0% 25.1% 29.3% 27.5%
--------------------------------------------------------------------------
(1) Change in local currencies.
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified
portfolio focused on branded medicines in gastroenterology, respiratory and
inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC
products completes the portfolio.
Its R&D is structured around collaborations. In-licensing and expanding in
emerging markets are cornerstones of the company's growth strategy.
Nycomed employs 12,500 associates worldwide, and its products are sold in more
than 100 countries. It has strong platforms in Europe and in fast-growing
markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US
and Japan its products are available through best in class partners.
Headquartered in Zurich, Switzerland, the company generated total sales of
? 3.2 billion in 2010 and an adjusted EBITDA of ? 851 million.
For more information visitwww.nycomed.com
For further information
Media:
General phone: +41 44 555 15 10
Tobias Cottmann, phone: +41 44 555 15 01
Investors:
Christian B. Seidelin, phone: +41 44 555 11 04
This press release has been issued by Nycomed International Management GmbH,
Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland.
--- End of Message ---
Nycomed
Thurgauerstrasse 130 Glattpark-Opfikon Switzerland
Press Release Nycomed Q2 2011 DE:
http://hugin.info/144179/R/1538924/470127.pdf
Press Release Nycomed Q2 2011 EN:
http://hugin.info/144179/R/1538924/470126.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Nycomed via Thomson Reuters ONE
[HUG#1538924]
Unternehmensinformation / Kurzprofil:
Datum: 17.08.2011 - 09:59 Uhr
Sprache: Deutsch
News-ID 57318
Anzahl Zeichen: 7528
contact information:
Town:
Glattpark-Opfikon
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nycomed reports double-digit growth across emerging markets in second quarter 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
Nycomed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
